[1] WANG Z, WU Z, LIU Y, et al.New development in CAR-T cell therapy[J]. J Hematol Oncol, 2017, 10(1): 53. [2] MAUDE SL, FREY N, SHAW PA, et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16): 1507-1517. [3] PORTER DL, HWANG WT, FREY NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J]. Sci Transl Med, 2015, 303(7): 303RA139. [4] CN-HEALTHCARE. The first domestic CAR-T is coming soon! China's CAR-T therapy does not lose to the United States, ushering in a blowout era! [EB/OL]. (2021-06-28)[2022-06-20]. https://www.cn-healthcare.com/articlewm/20210623/content-1234986.html?appfrom=jkj. [5] CN-HEALTHCARE. Acceptance and approval of domestic cell therapy products (as of March 9, 2022) [EB/OL].(2022-03-16)[2022-06-20]. https://www.cn-healthcare.com/articlewm/20220316/content-1326862.html. [6] NMPA. Technical guidelines for non-clinical research and evaluation of gene modified cell therapy products (trial version)[S]. National Medical Products Administration, 2021. [7] WEN H, QU Z, YAN Y, et al.Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice[J]. Ann Transl Med, 2019, 7(23): 735. [8] AGARWAL S, WEIDNER T, THALHEIMER FB, et al.In vivo generated human CAR T cells eradicate tumor cells[J]. Oncoimmunology, 2019, 8(12): e1671761. [9] LIU M, WANG X, LI Z, et al.Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro[J]. Cancer Sci, 2020, 111(11): 4051-4060. [10] KANG L, TANG X, ZHANG J, et al.Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes[J]. Exp Hematol Oncol, 2020, 9: 11. [11] WANG D, WU Y, MA Y, et al.Acute toxicitis of eight derviatives of fluorescein and their 50% lethal doses after intraperitoneal injection[J]. Journal of Lanzhou Medical College, 1989, 15(4): 189-193. [12] CHEN LY, KANG LQ, ZHOU HX, et al.Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia[J]. Transl Oncol, 2020, 13(11): 100838. [13] LIU ZF, CHEN LY, WANG J, et al.Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report[J]. Biomark Res, 2020, 8: 12. [14] SALOMAO M, DORRITIE K, MAPARA MY, et al.Histopathology of graft-vs-host disease of gastrointestinal tract and liver: an update[J]. Am J Clin Pathol, 2016, 145(5): 591-603. |